Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: Results of a multiinstitutional study (SJHG-98)

Cancer

Volumn 103, Issue 1, 2005, Pages 133-139

  Broniscer, Alberto ^a   Iacono, Lisa ^a   Chintagumpala, Murali ^b   Fouladi, Maryam ^a   Wallace, Dana ^a   Bowers, Daniel C ^c   Stewart, Clinton ^a   Krasin, Matthew J ^a   Gajjar, Amar ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Children; Diffuse brainstem glioma; Irinotecan; Temozolomide

Indexed keywords

5 (3 METHYLTRIAZEN 1 YL)IMIDAZOLE 4 CARBOXAMIDE; ATROPINE; DRUG METABOLITE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ANEMIA; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BRAIN STEM TUMOR; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HUMAN; HYPONATREMIA; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RASH; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN STEM NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; GLIOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; TREATMENT OUTCOME;

EID: 10844236514     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20741     Document Type: Article

References (26)

1. Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9:197-206.
2. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
3. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
4. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857.
5. Gilbert MR, Friedman HS, Kuttesch JF, et al. A Phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neurooncol. 2002;4:261-267.
6. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-1382.
7. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer. 1998;78:652-661.
8. Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol. 1998;16:3037-3043.
9. Panetta JC, Kirstein MN, Gajjar A, et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol. 2003;52:435-441.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34:585-612.
12. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology intergroup study. J Clin Oncol. 2002;20:4684-4691.
13. Louis DN, Rubio MP, Correa KM, Gusella JF, von Deimling A. Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. J Neuropathol Exp Neurol. 1993;52:507-515.
14. Zhang S, Feng X, Koga H, Ichikawa T, Abe S, Kumanishi T. p53 gene mutations in pontine gliomas of juvenile onset. Biochem Biophys Res Commun. 1993;196:851-857.
15. Sure U, Ruedi D, Tachibana O, et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol. 1997;56:782-789.
16. Cheng Y, Ng HK, Zhang SF, et al. Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol. 1999;30:1284-1290.
17. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9:3620-3624.
18. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999;17:2604-2613.
19. Hare CB, Elion GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase 1 inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1997;39:187-191.
20. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
21. Gilbert MR, Supko JG, Batchelor T, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940-2949.
22. Raymond E, Fabbro M, Boige V, et al. Multicentre Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003;14:603-614.
23. Blaney S, Berg SL, Pratt C, et al. A Phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001;7:32-37.
24. Vassal G, Doz F, Frappaz D, et al. A Phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21:3844-3852.
25. Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncol. 2002;4:102-108.
26. Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg. 2002;97:905-913.